This company listing is no longer active
Lattice Biologics (LBL) Stock Overview
A biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
LBL Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lattice Biologics Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.04 |
52 Week High | US$0.04 |
52 Week Low | US$0.04 |
Beta | 0 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | 100.00% |
Change since IPO | -88.24% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
LBL | CA Biotechs | CA Market | |
---|---|---|---|
7D | n/a | 0.4% | 0.6% |
1Y | n/a | 5.1% | 19.3% |
Return vs Industry: Insufficient data to determine how LBL performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how LBL performed against the Canadian Market.
Price Volatility
LBL volatility | |
---|---|
LBL Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 10.1% |
Market Average Movement | 9.2% |
10% most volatile stocks in CA Market | 18.2% |
10% least volatile stocks in CA Market | 3.6% |
Stable Share Price: LBL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LBL's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Guy Cook | n/a |
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; and acellular dermal matrix that provides a natural collagen tissue scaffold that promotes cellular ingrowth, tissue vascularization, and regeneration The company also develops amniotic fluid-based products, such as AmnioBoost and AmnioBlast. In addition, it sells traditional allografts for multi-disciplinary applications, including orthopedics, neurology, podiatry, and oral/maxillofacial.
Lattice Biologics Ltd. Fundamentals Summary
LBL fundamental statistics | |
---|---|
Market cap | CA$175.12 |
Earnings (TTM) | -CA$1.30m |
Revenue (TTM) | CA$2.13m |
Is LBL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LBL income statement (TTM) | |
---|---|
Revenue | US$1.56m |
Cost of Revenue | US$912.36k |
Gross Profit | US$645.64k |
Other Expenses | US$1.60m |
Earnings | -US$951.65k |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did LBL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/07/16 12:46 |
End of Day Share Price | 2024/07/15 00:00 |
Earnings | 2021/06/30 |
Annual Earnings | 2020/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lattice Biologics Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Siddharth Rajeev | Fundamental Research Corp. |